Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 10, 2022

BUY
$2.76 - $4.6 $372 - $621
135 Added 0.05%
257,513 $858,000
Q3 2021

Nov 10, 2021

BUY
$6.71 - $10.0 $1.73 Million - $2.57 Million
257,378 New
257,378 $1.76 Million

Others Institutions Holding INAB

About IN8BIO, INC.


  • Ticker INAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,502,200
  • Market Cap $8.33M
  • Description
  • IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...
More about INAB
Track This Portfolio

Track B. Riley Financial, Inc. Portfolio

Follow B. Riley Financial, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of B. Riley Financial, Inc., based on Form 13F filings with the SEC.

News

Stay updated on B. Riley Financial, Inc. with notifications on news.